Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: Evidence for a pathogenetic role of B cells

Arthritis and Rheumatism

Volumn 46, Issue 8, 2002, Pages 2029-2033

  De Vita, Salvatore ^a   Zaja, Francesco ^a   Sacco, Stefania ^a   De Candia, Alessandro ^a   Fanin, Renato ^a   Ferraccioli, Gianfranco ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD20 ANTIGEN; CYCLOSPORIN A; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; RHEUMATOID FACTOR; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EVALUATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; RELAPSE; RHEUMATOID ARTHRITIS; SYNOVITIS;

AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOSUPPRESSION; INFUSIONS, INTRAVENOUS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0036676817     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10467     Document Type: Article

References (14)

1. Cytokine pathways and joint inflammation in rheumatoid arthritis
2. Pathogenesis of rheumatoid arthritis: Role of B lymphocytes
3. B cells in rheumatoid arthritis
4. T cell activation in rheumatoid synovium is B cell dependent
5. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
6. Depletion of B cells in vivo by chimeric mouse human monoclonal antibody to CD20
7. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
8. Characterization of prelymphomatous stages of lymphoproliferation in Sjögren's syndrome
9. Rituximab (IDEC-C2B8): Validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study
10. Judging disease activity in clinical practice in rheumatoid arthritis: First step in the development of a disease activity score
11. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria
12. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
13. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
14. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia